Hemodialysis patient with chronic HCV infection, who was started on monotherapy with interferon. Qualitative HCV RNA remained positive at 12 weeks of treatment; ribavirin was associated. HCV RNA was negative at week 24 and treatment was extended to 72 weeks. HCV RNA negative six months after treatment.
Journal Information
Vol. 14. Issue 2.
Pages 193-196 (March - April 2010)
Vol. 14. Issue 2.
Pages 193-196 (March - April 2010)
Case report
Open Access
Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
Visits
2625
Aline Gonzalez Vigani1,
, Maria H.P. Pavan1, Raquel Tozzo1, Eduardo S.L. Gonçales1, Maria S.K. Lazarini1, Alexandre Macedo de Oliveira2, Fernando L. Gonçales Jr1
Corresponding author
aline.vigani@sigmanet.com.br
Correspondence to: Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas – UNICAMP Caixa-postal: 6198 Campinas – SP – Brazil, CEP: 13083-970, Phone: 55 29 35217727, Fax: 55 19 35217727.
Correspondence to: Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas – UNICAMP Caixa-postal: 6198 Campinas – SP – Brazil, CEP: 13083-970, Phone: 55 29 35217727, Fax: 55 19 35217727.
This item has received
Article information
Abstract
Keywords:
hepatitis C virus
hemodialysis
treatment
interferon
ribavirin
Full text is only aviable in PDF
References
[1.]
C.E. Gordon, K. Uhlig, J. Lau, C.H. Schmid, A.S. Levey, J.B. Wong.
Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.
Am J Kidney Dis., 51 (2008), pp. 263-277
[2.]
P. Dattolo, M. Lombardi, G. Ferro, S. Michelassi, T. Cerrai, F. Pizzarelli.
Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis.
G Ital Nefrol., 23 (2006), pp. 585-590
[3.]
F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, G. Dulai.
Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies.
Am J Transplant., 5 (2005), pp. 1452-1461
[4.]
D. Carriero, F. Fabrizi, A.J. Uriel, J. Park, P. Martin, D.T. Dieterich.
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Int J Artif Organs., 31 (2008), pp. 295-302
[5.]
E. Nakayama, T. Akiba, F. Marumo, C. Sato.
Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy.
J Am Soc Nephrol., 11 (2000), pp. 1896-1902
[6.]
E. Gane, H. Pilmore.
Management of chronic viral hepatitis before and after renal transplantation.
Transplantation, 74 (2002), pp. 427-437
[7.]
P. Mathurin, C. Mouquet, T. Poynard, C. Sylla, H. Benalia, C. Fretz, et al.
Impact of hepatitis B and C virus on kidney transplantation outcome.
Hepatology, 29 (1999), pp. 257-263
[8.]
G.A. Knoll, M.R. Tankersley, J.Y. Lee, B.A. Julian, J.J. Curtis.
The impact of renal transplantation on survival in hepatitis C-positive endstage renal disease patients.
Am J Kidney Dis., 29 (1997), pp. 608-614
[9.]
N. Kamar, O. Toupance, M. Buchler, K. Sandres-Saune, J. Izopet, D. Durand, et al.
Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation.
J Am Soc Nephrol., 14 (2003), pp. 2092-2098
[10.]
F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, P. Martin.
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.
Aliment Pharmacol Ther., 18 (2003), pp. 1071-1081
[11.]
M.W. Russo, C.D. Goldsweig, I.M. Jacobson, R.S. Brown Jr.
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.
Am J Gastroenterol., 98 (2003), pp. 1610-1615
[13.]
M. Rendina, A. Schena, N.M. Castellaneta, F. Losito, A.C. Amoruso, G. Stallone, et al.
The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
J Hepatol., 46 (2007), pp. 768-774
[14.]
A. Bruchfeld, L. Ståhle, J. Andersson, R. Schvarcz.
Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study.
J Viral Hepat., 8 (2001), pp. 287-292
[15.]
F. Fabrizi, F.F. Poordad, P. Martin.
Hepatitis C infection and the patient with end-stage renal disease.
Hepatology, 36 (2002), pp. 3-10
[16.]
S. Pol, F. Carnot, B. Nalpas, J.L. Lagneau, H. Fontaine, J. Serpaggi, L. Serfaty, P. Bedossa, C. Bréchot.
Reversibility of hepatitis C virus-related cirrhosis.
Hum Pathol., 35 (2004), pp. 107-112
[17.]
S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, D. Cazals-Hatem, et al.
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Gastroenterology, 135 (2008), pp. 821-829
[18.]
U. Mihm, E. Herrmann, C. Sarrazin, S. Zeuzem.
Review article: predicting response in hepatitis C virus therapy.
Aliment Pharmacol Ther., 23 (2006), pp. 1043-1054
[19.]
T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, T. Gerlach, et al.
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Gastroenterology, 130 (2006), pp. 1086-1097
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved